Molecular neuroimaging in the study of cognitive impairment: Contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan;La neuroimagen molecular en el estudio del deterioro cognitivo: contribución de la SPECT de perfusión cerebral con 99mTc-HMPAO y la 18F-FDG PET/TAC

Revista Espanola de Medicina Nuclear

Volumn 30, Issue 5, 2011, Pages 301-306

  Banzo, I ^a   Quirce, R ^a   Martinez Rodriguez I ^a   Jimenez Bonilla J ^a   Portilla Quattrociocchi, H ^a   Medina Quiroz, P ^a   Ortega, F ^a   Rodriguez E ^a   Mateo, I ^a   Vazquez Higuera J L ^a   de Arcocha, M ^a   Carril, J M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Alzheimer's disease; Cerebral blood flow SPECT; Glucose metabolism; Mild cognitive impairment

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; BRAIN REGION; CLINICAL ARTICLE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; GLUCOSE METABOLISM; HUMAN; MEMORY DISORDER; NEUROIMAGING; PERFUSION; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 80051952279     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/j.remngl.2011.03.011     Document Type: Article

References (34)

1. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., et al. Global prevalence of dementia: a delphi consensus study. Lancet 2005, 366:2112-2117.
2. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
3. Reisberg B., Ferris S.H., Kluger A., Franssen E., Wegiel J., de León M.J. Mild cognitive impairment (MCI): a historical perspective. Int Psychogeriatr 2008, 20:18-31.
4. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., DeKosky S.T. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001, 56:1133-1142.
5. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kommen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
6. Hort J., O'Brien J.T., Gainotti G., Pirttila T., Popescu B.O., Rektorova I., et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010, 17:1236-1248.
7. Martí-Climent J.M., Prieto E., López Lafuente J., Arbizu J. Neuroimagen: fundamentos técnicos y prácticos. Rev Esp Med Nucl 2010, 29:189-210.
8. Carril J.M., MacDonald A.F., Dendy P.P., Keyes W.I., Undrill P.E., Mallard J.R. Cranial scintigraphy: value of adding emission computed tomographic sections to conventional pertechnetate images (512 cases). J Nucl Med 1979, 20:1117-1123.
9. Quirce R., Carril J.M., Jiménez-Bonilla J.F., Amado J.A., Gutiérrez-Mendiguchía C., Banzo I., et al. Semi-quantitative assessment of cerebral blood flow with 99mTc-HMPAO SPET in type I diabetic patients with no clinical history of cerebrovascular disease. Eur J Nucl Med 1997, 24:1507-1513.
10. Jiménez-Bonilla J.F., Quirce R., Banzo I., Martínez-Rodríguez I., Sáinz-Esteban A., Portilla H., et al. Temporal hypoperfusion assessed by cerebral blood flow SPECT and long-term clinical outcome in patients with eating disorders. Clin Nucl Med 2009, 34:768-772.
11. Fletcher J.W., Djulbegovic B., Soares H.P., Siegel B.A., Lowe V.J., Lyman G.H., et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008, 49:480-508.
12. Podoloff D.A., Advani R.H., Allred C., Benson A.B., Brown E., Burstein H.J., et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Cancer Netw 2007, 5(Supl 1):S1-22.
13. Silverman D.H.S., Mosconi L., Ercoli L., Chen W., Small G.W. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Sem Nucl Med 2008, 38:251-261.
14. Reisberg B., Ferris S.H., de León M.J., Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982, 139:1136-1139.
15. Dubois B., Albert M.L. Amnestic MCI or prodromal Alzheimer's disease?. Lancet Neurol 2004, 3:246-248.
16. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
17. Arbizu J., Domínguez P.D., Díez-Valle R., Vigil C., García-Eulate R., Zubieta J.L., et al. Neuroimagen de los tumores cerebrales. Rev Esp Med Nucl 2011, 30:47-65.
18. Kadir A., Nordberg A. Target-specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med 2010, 51:1418-1430.
19. Breteler M.M.B. Mapping out biomarkers for Alzheimer's disease. JAMA 2011, 305:304-305.
20. Masdeu J.C., Zubieta J.L., Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer's disease. J Neurol Sci 2005, 236:55-64.
21. Gautier S., Reisberg B., Zaudig M., Petersen R.C., Ritchie K., Broich K., et al. Mild cognitive impairment. Lancet 2006, 367:1262-1270.
22. Mosconi L., De Santi S., Brys M., Tsui W.H., Pirraglia E., Glodzik-Sobanska L., et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 2008, 63:609-618.
23. Huang C., Wahlund L.O., Svensson L., Winblad B., Julin P. Cingulate cortex hipoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol 2002, 2:9.
24. Hirao K., Ohnishi T., Hirata Y., Yamashita F., Mori T., Moriguchi Y., et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using cerebral blood flow SPECT. Neuroimage 2005, 28:1014-1021.
25. Matsuda H. Role of neuroimaging in Alzheimer's disease with emphasis on brain perfusion SPECT. J Nucl Med 2007, 48:1289-1300.
26. Wolf H., Jelic V., Gertz H.U., Nordberg A., Julin P., Wahlud L.O. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand 2003, 179:52-76.
27. Jobst K.A., Bametson L.P., Shepstone B.J. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO e{open}4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging. Int Psychogeriartr 1998, 10:271-302.
28. Herholz K. Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. Expert Rev Neurother 2010, 10:1667-1673.
29. Mosconi L., Mistur R., Switalski R., Tsui W.H., Glodzik L., Li Y., et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer' disease. Eur J Nucl Med Mol Imaging 2009, 36:811-822.
30. Nestor P.J., Fryer T.D., Smielewki P., Hodges J.R. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003, 54:343-351.
31. Drzezga A., Lautenschlager N., Siebner H., Riemenschneider M., Willoch F., Minoshima S., et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003, 30:1104-1113.
32. Mosconi L., De Santi S., Li Y., Zhan J., Tsui W.H., Boppana M., et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med Mol Imaging 2006, 33:210-221.
33. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004, 55:306-319.
34. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Pontecorvo M.J., et al. Use of Florbetapir-PET for imaging β-amyloid pathology. JAMA 2011, 305:275-283.